ダウンロード数 : ?
言語
英語
著者
Sato Shuichi Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan
Miyake Tatsuya Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan
石原 俊治 医学部内科学講座内科学第二
主題
nonalcoholic; steatohepatitis; type 2 diabetes mellitus; sodium-glucose; cotransporter 2-inhibitor; dapagliflozin; open-label
掲載誌名
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
87
開始ページ
13
終了ページ
19
ISSN
0011-393X
ISSN(Online)
1879-0313
発行日
2017
DOI
PubMed ID
出版者
ELSEVIER SCIENCE INC
資料タイプ
学術雑誌論文
部局
医学部
備考
Dapagliflozin was developed by AstraZeneca, who provided funding for publication fees and development of the manuscript, but did not play any other role in the study design; collection, analysis, and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication. HT and YK have received honoraria from AstraZeneca K.K. Funding to pay for editorial support and the Open Access publication charges for this article were provided by AstraZeneca K.K. and Ono Pharmaceutical Co, Ltd. The authors have indicated that they have no other conflicts of interest regarding the content of this article.